drug

Cancer drug company accuses U.S. market makers of stock usurpation

Cancer drug company accuses U.S. market makers of stock usurpation

Leave a Comment / Markets / By

A cancer-focused biotech company has sued eight of America’s biggest traders, including Citadel Securities, Susquehanna and Virtu, alleging they deliberately depressed its stock price by placing sell orders they didn’t have not intend to perform. The lawsuit, filed Thursday by Northwest Biotherapeutics in federal court in New York, alleged that marketers “deliberately engaged in repeated …

Cancer drug company accuses U.S. market makers of stock usurpation Read More »

Drug slows cognitive decline in Alzheimer’s patients, study finds

Leave a Comment / Business / By

Researchers have hailed the dawn of a new era of therapies for Alzheimer’s disease after a clinical trial confirmed that a drug slows cognitive decline in patients in the early stages of the disease. The result comes after decades of failure in the field and has encouraged experts to say that Alzheimer’s disease – which …

Drug slows cognitive decline in Alzheimer’s patients, study finds Read More »

In turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions

In turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions

Leave a Comment / Business / By

After the FDA rejected and questioned Ardelyx’s potential drug for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis, the FDA’s Cardiovascular and Kidney Drug Advisory Committee voted Wednesday 9-4 in favor of the drug as monotherapy, and 10-2 (with one abstention) in favor of the drug when given in combination with …

In turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions Read More »

Roche's Alzheimer's drug fails in long-awaited trial

Roche’s Alzheimer’s drug fails in long-awaited trial

Leave a Comment / Business / By

Trials show small benefit, but without statistical validity Roche setback leaves Biogen and Eisai as leaders in the field It’s up to Roche’s CEO-designate to revive development fortunes Roche shares down 3.4%, its development partner Morphosys down 29% Nov 14 (Reuters) – Roche’s (ROG.S) Alzheimer’s drug candidate has not been shown to slow the progression …

Roche’s Alzheimer’s drug fails in long-awaited trial Read More »